We realize that the effects of this COVID-19 pandemic are causing a metal health crisis now and for the foreseeable future. Some patients no longer have access to TMS, yet the direct and indirect effects of the COVID-19 epidemic are increasing the number of people needing TMS therapy. Here at Magstim, we are working diligently to design innovative solutions and are scaling up to effectively meet this increasing demand. We are in this together and welcome your collaboration. Please share your ideas, questions, and concerns.
Magstim is continuing to develop solutions that will provide greater access for patients who need TMS therapy. Our FDA-cleared 3-minute treatment allows practitioners to reduce exposure and treat more patients within the safety guidelines. Additionally, our StimGuide clinical navigation system enables both novice and expert treaters to effectively administer TMS consistently to a precise location – allowing practices to potentially treat more patients during this increased demand.
As we navigate these troubled waters, we remain as committed to you as you are to your patients.
Thank you for your trust and partnership.